Phase III, Multicenter, Open-label, Randomized Trial of Tarceva vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR

Trial Profile

Phase III, Multicenter, Open-label, Randomized Trial of Tarceva vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2018

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Cisplatin; Docetaxel; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms EURTAC
  • Most Recent Events

    • 23 Mar 2018 Results (n=1312) assessing the value of early depth of response in predicting long-term outcome in EGFR-mutant lung cancer using data of patients those with either EGFR mutation exon 19 deletion or exon 21 L858R mutations from five phase III randomized trials EURTAC, IPASS, ENSURE, LUX-Lung 3, and LUX-Lung 6, published in the Journal of Thoracic Oncology.
    • 18 Oct 2017 Results assessing Overall survival Adjusting for Post-Progression Treatment Crossover in three phase III trials (EURTAC, ENSURE and OPTIMAL), presented at the 18th World Conference on Lung Cancer
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top